Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
97%
Multiple Myeloma
92%
Rituximab
76%
Myeloma
72%
Tumor
72%
FDG-PET Scan
61%
Comets
61%
Phase II Clinical Trial
61%
Thalidomide
61%
Maintenance Therapy
61%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
61%
Clinical Laboratory
61%
Japan
60%
Thrombocytopenia
58%
Liver
56%
Central Nervous System
51%
Lymphoma Cells
51%
Malignant Lymphoma
46%
Lymphoma
43%
Multiple Myeloma Patients
41%
B-cell Lymphoma
41%
Laboratory Medicine
39%
Hematology
37%
Differential Diagnosis
36%
Medical Students
35%
Indolent Lymphoma
34%
Clinical Practice
34%
C-X-C Chemokine Receptor Type 4 (CXCR4)
34%
Chemokine Ligand 12 (CXCL12)
34%
IgG4-related Disease (IgG4-RD)
34%
Prognostic Factors
32%
Atypical Manifestations
30%
Adult T-cell Leukemia
30%
Practice Training
30%
Positron Emission Tomography
30%
Genetic Diagnostics
30%
Splicing Abnormality
30%
In Vivo Growth
30%
Treatment Strategy
30%
TAFRO Syndrome
30%
Disease Severity
30%
Classification Strategy
30%
Cladribine
30%
Oncohematology
30%
Bone Microenvironment
30%
Chemokine CX3CL1
30%
Velpatasvir
30%
Nontransplant
30%
Sofosbuvir
30%
Anaplastic Large Cell Lymphoma
30%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
30%
CX3CR1
30%
Diagnostic Criteria
30%
Mouse Model
30%
Lymphoid Follicles
30%
Plasma Infusion
30%
Overall Survival
30%
Hepatocellular Carcinoma
30%
IgM Antibody
30%
Prospective Clinical Study
30%
Human Hepatoma
30%
Gastric Neuroendocrine Carcinoma
30%
Synapse
30%
Adult-onset Type II Citrullinemia
30%
Hospital Meals
30%
CTLN2
30%
Non-Hodgkin Lymphoma
30%
Infectious Mononucleosis
30%
Tumor Necrosis Factor-α
30%
Quantification Assay
30%
Laboratory Data
30%
Human Hepatocellular Carcinoma
30%
Lysophosphatidic Acid
30%
Chronic Hepatitis C
30%
International Journals
30%
Treatment Factors
30%
Amoxicillin
30%
Lafutidine
30%
Routine Laboratory
30%
Triple Therapy
30%
Cytomegalovirus
30%
Rabeprazole
30%
Prognostic Model
30%
Serine-threonine Kinase
30%
Neurotransmitter Release
30%
Oncology Studies
30%
Successful Treatment
30%
Screening Approach
30%
Chemotherapy
30%
Nationwide Survey
30%
Burkitt Lymphoma
30%
R-CHOP
30%
Leukemia
30%
Metronidazole
30%
Soluble interleukin-2 Receptor (sIL-2R)
30%
Thrombotic Thrombocytopenic Purpura
30%
High-throughput
30%
Novel Therapeutic Targets
30%
Piperacillin
30%
Lysophosphatidylcholine
30%
Medicine and Dentistry
Neoplasm
100%
Positron Emission Tomography
92%
Rituximab
87%
B-Cell Lymphoma
85%
Thrombocytopenia
74%
Diffuse Large B-Cell Lymphoma
67%
Multiple Myeloma
61%
Hematology
61%
Diagnosis
53%
Lymphoma
46%
Follicular Lymphoma
41%
Transplantation
38%
Chemotherapy
38%
Myeloma
37%
Ascites
36%
Differential Diagnosis
36%
Recurrent Disease
36%
Overall Survival
30%
Thalidomide
30%
Clinical Trial
30%
Fluorodeoxyglucose
30%
Maintenance Therapy
30%
Fractalkine
30%
Angiofollicular Lymph Node Hyperplasia
30%
Disease Severity
30%
Cladribine
30%
Central Nervous System
30%
Adult T-Cell Leukemia/Lymphoma
30%
Velpatasvir
30%
Sofosbuvir
30%
Anaplastic Large Cell Lymphoma
30%
Dendritic Cell Function
30%
IgG4-Related Disease
30%
Neuroendocrine Carcinoma
30%
Piperacillin
30%
Dexamethasone
30%
Immunoglobulin M Antibody
30%
Non-Hodgkin Lymphoma
30%
Citrullinemia Type II
30%
Infectious Mononucleosis
30%
Cytomegalovirus
30%
Leukemia
30%
Clinical Study
30%
Soluble Interleukin 2 Receptor
30%
Burkitt's Lymphoma
30%
Decompensated Liver Cirrhosis
30%
Antibody Response
30%
Natural Killer Cell
30%
Mitoxantrone
30%
Lacrimal Gland
30%
Mantle Cell Lymphoma
30%
Liver Venoocclusive Disease
30%
Oncology
30%
Stromal Cell Derived Factor 1
30%
Metastatic Carcinoma
30%
Stomach Adenocarcinoma
30%
Thrombotic Thrombocytopenic Purpura
30%
Plasma Transfusion
30%
T Cell
29%
Disease
28%
Inflammatory Disorder
25%
Mucosa-Associated Lymphoid Tissue
23%
Tissue (Anatomy)
23%
Lymphadenopathy
23%
Hematopoietic Stem Cell Transplantation
23%
Dendritic Cell
22%
Fluorodeoxyglucose F 18
21%
Waldenström's Macroglobulinemia
20%
Hepatitis C
20%
Hazard Ratio
19%
Pleura Effusion
19%
Intrathecal Drug Administration
18%
Lenalidomide
18%
Epstein Barr Virus
18%
Platelet
18%
Serositis
16%
Protein Losing Enteropathy
15%
Renal Failure
15%
Glucocorticoid
15%
Tocilizumab
15%
Cyclosporine
15%
Immunosuppressant
15%
Organomegaly
15%
Anasarca
15%
Hepatosplenomegaly
15%
Trimethoprim
15%
Sulfamethoxazole
15%
Eyelid
15%
Cancer
15%
Allogeneic Peripheral Blood Stem Cell Transplantation
15%
Hemophagocytic Syndrome
15%
Pneumocystis Pneumonia
15%
T Cell Receptor
15%
Human T-Lymphotropic Virus 1
15%
Lymphoid Leukemia
15%
Myelodysplastic Syndrome
15%
Eating Habit
15%
Amino Acid
15%
Carbohydrate Analysis
15%
Lactulose
15%